Catheter fragmentation and local lysis in two lung transplant patients with pulmonary embolism.
In conjunction with the rising number of lung transplant operations in the past decade, an increased predisposition to venous thrombosis (VT), particularly within the first year posttransplantation has been observed. Previous studies have revealed that between 8.6% and 12% of patients develop VT, which can ultimately result in pulmonary emboli (PE).Transplanted lungs pose a much greater infarction risk due to their lack of collateral vascularisation, relying entirely on the vasa publica--the pulmonary artery--in the absence of vasa privata. Such losses in viable lung parenchyma are always serious, but carry still greater risks for single-lung transplant recipients, an early diagnosis and treatment remain critical. Here we report on two cases of PE after lung transplantation, both of whom were managed with catheter fragmentation and local thrombolysis. In our opinion, this approach represents a viable treatment for symptomatic PE in lung transplant recipients. The benefits and risks of the alternative treatment options in these special cases will be reviewed and the definitive therapy was described. In the patients treated, catheter fragmentation with localized thrombolysis resulted in short term improvements in graft function, but could not prevent later lung infarction in one case.
Suhling
H
H
Department of Respiratory Medicine Department of Cardiology and Angiology Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hanover Medical School, Hanover, Germany. suhling.hendrik@mh-hannover.de
Westerkamp
V
V
Dinh
Q T
QT
Greer
M
M
Kempf
T
T
Simon
A
A
Gottlieb
J
J
Welte
T
T
Schieffer
B
B
D000328:Adult; D001989:Bronchiolitis Obliterans / Q000209:etiology / Q000628:therapy; D057785:Catheters; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000209:etiology* / Q000628:therapy*; D017131:Thrombectomy
D005343:Fibrinolytic Agents